Shayan Ramin, Sharifzadeh Seyyed-Reza, Sadeghian Amirhossein, Fallah Ehsan
Trauma and Surgery Research Center, Aja University of Medical Science Tehran, Iran.
School of Medicine, Zabol University of Medical Sciences Sistan and Baluchestan, Iran.
Int J Burns Trauma. 2025 Jun 15;15(3):133-142. doi: 10.62347/JZYC7897. eCollection 2025.
This study evaluated the efficacy of precise platelet-rich plasma (PRP) injection, guided by arthroscopy, in patients with grade II meniscus tears.
The study protocol was reviewed and approved by the Institutional Review Board (IRB) of AJA University of Medical Sciences (Code: IR.AJAUMS.REC.1399.258). This study has also been approved by Iranian Registry of Clinical Trials (IRCT) with the code of: IRCT20200217046523N18. In this study, 90 patients with grade II meniscus tears, randomly assigning them to either a PRP injection group (n=45) or a conservative treatment control group (n=45) were enrolled. All patients included in the study had anterior cruciate ligament (ACL) tears and underwent arthroscopic ACL reconstruction. PRP was prepared using a standardized protocol, and injection was performed under arthroscopic guidance using a specialized cannulated loop navigator. Outcomes were assessed using magnetic resonance imaging (MRI) evaluation at baseline, 6, and 12 months post-intervention, and clinical evaluations at the same time points.
While the PRP group showed a trend towards improved meniscus tear healing compared to the control group at 6 months (P=0.0552), this difference was not statistically significant at either 6 or 12 months. Similarly, clinical scores showed slight improvements in the PRP group over time, but these differences were not statistically significant compared to baseline or the control group.
This study did not demonstrate statistically significant superior outcomes with precise arthroscopically-guided PRP injection as a standalone treatment for grade II meniscus tears compared to conservative management at 6 and 12-month follow-up. Further research with larger sample sizes and longer follow-up periods is needed to definitively assess the role of PRP in the management of grade II meniscus tears.
本研究评估了在关节镜引导下精确注射富血小板血浆(PRP)对Ⅱ级半月板撕裂患者的疗效。
该研究方案经阿贾医科大学机构审查委员会(IRB)审查并批准(代码:IR.AJAUMS.REC.1399.258)。本研究也已获得伊朗临床试验注册中心(IRCT)批准,代码为:IRCT20200217046523N18。在本研究中,90例Ⅱ级半月板撕裂患者被随机分为PRP注射组(n = 45)或保守治疗对照组(n = 45)。纳入研究的所有患者均有前交叉韧带(ACL)撕裂,并接受了关节镜下ACL重建术。PRP采用标准化方案制备,并在关节镜引导下使用专门的空心环导航器进行注射。在干预前、干预后6个月和12个月使用磁共振成像(MRI)评估结果,并在相同时间点进行临床评估。
虽然PRP组在6个月时与对照组相比显示出半月板撕裂愈合改善的趋势(P = 0.0552),但在6个月或12个月时,这种差异均无统计学意义。同样,PRP组的临床评分随时间略有改善,但与基线或对照组相比,这些差异无统计学意义。
本研究未证明在6个月和12个月的随访中,与保守治疗相比,精确的关节镜引导下PRP注射作为Ⅱ级半月板撕裂的独立治疗方法具有统计学上显著的更好疗效。需要进一步进行更大样本量和更长随访期的研究,以明确评估PRP在Ⅱ级半月板撕裂治疗中的作用。